Everyone in this community has either asked or been asked the same uncomfortable question: what happens when you come off the drug? The honest answer has always been “regain, usually most of it,” and the honest follow-up has been “but nobody has really tested what works about that.” Until now, there has been very little actual evidence about what to do in the months after stopping, as opposed to endless hand-waving about diet and exercise.
A new pilot randomised controlled trial published this month in Obesity Science and Practice has finally started to fill that gap, and the headline finding is stark: in the group that got ordinary care after stopping their GLP-1, weight came back at a rate of nearly 3 percent per month. In the two groups that got structured support, it barely moved.
The study design, briefly
The paper, from Hollis-Hansen and colleagues at the University of Texas Southwestern Medical Center, is a small study - only 39 people - and we will be upfront about that. But it is a randomised controlled trial, which puts it a long way above the anecdote pile, and it asked a question nobody had asked in this exact form before.
The design: recruit people who had lost at least 10 percent of their body weight on a GLP-1 receptor agonist and had stopped the drug within the past 30 days. On average, participants had lost 18.1 percent of their body weight while on the medication. Then randomise them into three groups for four months:
- Usual care - whatever advice their own provider gave them, which in practice meant little or nothing structured.
- A digital wellness application - a Noom subscription, with daily behavioural lessons, food logging, and self-monitoring.
- Medically tailored meals - ten dietitian-developed, portion-controlled home-delivered meals per week, around 372 dollars a month worth of food, covering 40 meals a month.
Everyone got a Bluetooth scale and weighed in monthly. The study ran from March 2024 to August 2025, was fully remote, and was approved by the UT Southwestern human research ethics committee.
The results are striking
Over four months, the usual-care group regained an estimated 10.75 percent of their body weight - a slope of 2.94 percent per month. If you extrapolate that trend, they would be on track to regain most or all of what the drug had taken off inside a year. That matches the observational literature, which has consistently found that people regain roughly half their lost weight within 12 months of stopping a GLP-1, but seeing it happen in real time in a randomised group is different from reading it in a retrospective chart review.
The two intervention groups? Both regained around 3.6 percent total over four months, a slope of under 0.7 percent per month. The difference versus usual care was about minus 7.2 percentage points for both arms, with p values of 0.006 and 0.007. In plain terms: structured support cut the regain rate by roughly three-quarters during the highest-risk window, which longitudinal data shows is the first three to four months after stopping.
The other thing worth noticing: it did not matter much which structured support they got. The app and the meals produced almost identical numbers, and both beat usual care by the same margin. The authors did not find significant differences between the two interventions. That suggests the active ingredient might be structure itself - having a plan, having accountability, having something tracking what you eat - rather than any particular mechanism.
Why this matters to the maintenance conversation
The context behind this study is the mess around access and affordability. Only about 19 percent of people have insurance coverage for GLP-1 weight-loss treatment, and somewhere between 20 and 50 percent of people discontinue within the first year - some because of cost, some because of side effects, some because they hit their goal and assume the work is done. In Australia the dynamics are slightly different, with compounding pathways closing to GLP-1 analogues since October 2024 and telehealth providers now under TGA scrutiny for advertising, but the underlying question is the same everywhere: if you cannot or will not stay on the drug forever, what is plan B?
The research here does not say stop the drug. The authors are explicit that discontinuation is not clinically recommended and that GLP-1s remain among the most effective long-term weight management strategies available. What the study says is that if stopping happens anyway - and it happens a lot - the first four months are the danger zone, and structured support during that window appears to blunt a big chunk of the regain. Not all of it, note: 3.6 percent is not zero.
What the Research Says
- Hollis-Hansen K et al., “Preventing Weight Regain After Glucagon-Like Peptide-1 Therapy Discontinuation: A Pilot Randomized Controlled Trial,” Obesity Science and Practice, 2026, DOI: 10.1002/osp4.70194. Thirty-nine adults who had lost at least 10 percent of body weight on a GLP-1 and stopped within 30 days were randomised to usual care, a digital wellness app, or medically tailored meals for four months.
- Total regain at four months: 10.75 percent in usual care versus 3.60 percent (app) and 3.58 percent (meals). Monthly regain slope: 2.94 percent in usual care versus 0.42 percent and 0.61 percent in the intervention arms. Differences versus control of roughly minus 7.2 percentage points, p less than 0.01 for both interventions.
- Background epidemiology in the same paper: longitudinal studies show steep regain in the first three to four months after abrupt GLP-1 discontinuation, and most patients regain at least half their lost weight within a year. Around 20 to 50 percent of patients discontinue within the first year of starting.
- This is a pilot study with 39 participants and wide confidence intervals on the group differences. The authors frame it as hypothesis-generating, and a larger, longer follow-up study is in preparation. Do not treat a pilot as settled science.
The Australian angle
If you are in Australia and this topic feels urgent, that is because the landscape here has its own complications. The TGA’s ban on pharmacist-compounded GLP-1 analogues took effect in October 2024, which pushed people who could not access or afford approved pens into a grey market with all the quality problems we have documented - mislabelled vials, wrong compounds, wildly wrong doses. Meanwhile the regulator has been active on the telehealth side, warning providers in mid-October about advertising rules around waitlists for unapproved oral GLP-1 products.
The lesson that keeps coming back is that transitions are where things go wrong. Coming off a drug, switching products, losing access - those are the moments when people either have a plan or get overwhelmed. This study is one of the first to actually measure whether a plan helps, and the answer is a fairly emphatic yes.
If you are navigating the Australian access landscape, our semaglutide, tirzepatide and CagriSema pages have background on the approved and investigational options, and the Grey Highway Telegram group is where the community compares notes on what actually works when the script runs out.
The takeaway
Regain after stopping a GLP-1 is not a moral failure or a sign the drug did not work. It is a predictable physiological rebound - the body has compensatory adaptations that increase hunger and lower energy expenditure after weight loss, and those do not care that you are proud of your progress. What this trial shows is that the rebound can be interrupted with structure, and that the specific structure matters less than having one.
Four months, 39 people, one pilot study. It is not the last word. But it is the first real word on a question everyone was guessing about, and it points somewhere more useful than the usual advice.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.